<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03548454</url>
  </required_header>
  <id_info>
    <org_study_id>44758</org_study_id>
    <nct_id>NCT03548454</nct_id>
  </id_info>
  <brief_title>Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization</brief_title>
  <official_title>Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over 100 million Americans suffer from chronic pain resulting in annual cost of roughly $635
      billion. Limited treatments are available for this widespread disease. The data supporting
      these treatments lack generalizability to patients with more serious medical and
      psychological comorbidities who are often excluded from explanatory efficacy trials. Our work
      aims to integrate randomized comparative effectiveness research with patient care. The
      investigators will randomize the patients and collect data using an open-source learning
      healthcare system already in use in our department to monitor patients' progress:
      Collaborative Health Outcomes Information Registry (CHOIR). Collaborative Health Outcomes
      Information Registry uses the National Institute of Health Patient Reported Outcomes
      Measurement Information System item banks for comparative metrics through computer adaptive
      testing. The investigators will leverage the advantage of this novel system to compare
      effectiveness of duloxetine and desipramine in decreasing pain in patients with chronic pain.
      The investigators will also compare adherence of patients to these two commonly used
      medications over a period of six months. This will evaluate feasibility of integrating
      randomized comparative effectiveness research with patient care in subspecialty clinics.
      Collaborative Health Outcomes Information Registry can then be applied for numerous future
      trials to advance our knowledge in perioperative and pain medicine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity</measure>
    <time_frame>Monthly for 6 months</time_frame>
    <description>Average and worst pain intensity reported by participants on a numerical rating scale of 0-10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical Function</measure>
    <time_frame>Monthly for 6 months</time_frame>
    <description>National Institute of Health Patient Reported Outcomes Measurement Information System Standardized score for physical function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Interference</measure>
    <time_frame>Monthly for 6 months</time_frame>
    <description>National Institute of Health Patient Reported Outcomes Measurement Information System Standardized score for pain interference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Monthly for 6 months</time_frame>
    <description>National Institute of Health Patient Reported Outcomes Measurement Information System Standardized score for depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Monthly for 6 months</time_frame>
    <description>National Institute of Health Patient Reported Outcomes Measurement Information System Standardized score for anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>Monthly for 6 months</time_frame>
    <description>Time to stopping either medication in days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine starting at 20 mg per day and increasing to 60 mg per day as tolerated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desipramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desipramine starting at 25 mg per day and increasing to 75 mg per day as tolerated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Open label prescription</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desipramine</intervention_name>
    <description>Open label prescription</description>
    <arm_group_label>Desipramine</arm_group_label>
    <other_name>Norpramin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Age of 18 years old or above

          2. Persistent pain for more than 3 months

          3. Candidate for treatment by anti-depressant based on treating pain provider

        Exclusion criteria:

          1. Prior failure of duloxetine and/or desipramine (patients who have failed other TCAs or
             SNRIs can be considered for the trial based on the reason for previous medication
             failure)

          2. Contraindication to taking duloxetine or desipramine

          3. Patient refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vafi Salmasi, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vafi Salmasi, MD.</last_name>
    <phone>650-725-0246</phone>
    <email>vsalmasi@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Pain Management Center</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vafi Salmasi, MD.</last_name>
      <phone>650-725-0246</phone>
      <email>vsalmasi@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Vafi Salmasi</investigator_full_name>
    <investigator_title>Clinical Instructor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Desipramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

